Q32 Bio
QTTB
About: Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.
Employees: 27
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
33% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 4 (+1) [Q2]
3.5% less ownership
Funds ownership: 77.11% [Q1] → 73.61% (-3.5%) [Q2]
14% less capital invested
Capital invested by funds: $15.5M [Q1] → $13.4M (-$2.16M) [Q2]
18% less funds holding
Funds holding: 71 [Q1] → 58 (-13) [Q2]
37% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 19
59% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 22
Financial journalist opinion
